BCL2L2 and ovarian cancer: When BCL2L2 expression was inhibited by miR‐335‐5p, the DDP resistance of ovarian cancer cells was significantly alleviated, resulting in an accelerating cell apoptosis and cell cycle arrest at G1 phase.